Windlas Biotech Limited has announced a scheduled virtual meeting with analysts and institutional investors, set to take place on April 20, 2026. The pharmaceutical company formally notified both BSE Limited and National Stock Exchange of India Limited about this investor engagement on April 15, 2026.

Meeting Details and Schedule

The company has organized a group investor meeting with the following specifications:

Regulatory Compliance and Information Sharing

The notification was issued pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Windlas Biotech has explicitly stated that the company will reference only publicly available documents during discussions with investors and analysts.

The company has provided clear assurance that no unpublished price sensitive information (UPSI) will be shared during the meeting, maintaining compliance with regulatory requirements for investor interactions.

Administrative Details

Company Secretary and Compliance Officer Ananta Narayan Panda signed the official notification, acknowledging that potential schedule changes may occur due to exigencies on the part of investors, analysts, or the company itself. The notification was formally submitted to both major Indian stock exchanges on April 15, 2026.

This investor meeting represents part of Windlas Biotech's ongoing engagement with the investment community, providing a platform for discussions about the company's operations and performance based on publicly disclosed information.

Windlas biotech Limited has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE and NSE on April 6, 2026.

Quarterly Compliance Certificate Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The document pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Key Confirmation

MUFG Intime India Private Limited confirmed that during the quarter ended March 31, 2026, no demat requests were received for processing. The registrar specifically noted that Windlas Biotech Limited does not have any physical shares outstanding, indicating that all shares are already in dematerialized form.

Regulatory Compliance

The submission was made to the compliance departments of both major Indian stock exchanges. Company Secretary and Compliance Officer Ananta Narayan Panda signed the filing letter, ensuring adherence to regulatory requirements. This quarterly certificate filing is a standard compliance requirement for listed companies under SEBI regulations.

Company Information

Windlas Biotech Limited operates from its registered office in Dehradun, Uttarakhand, with its corporate office located in Gurgaon, Haryana. The company maintains its listing on both BSE and NSE, trading under the symbols 543329 and WINDLAS respectively.